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Abstract
Background: Patients with germline mutations in a tumour suppressor gene called CYLD develop multiple,
disfiguring, hair follicle tumours on the head and neck. The prognosis is poor, with up to one in four mutation
carriers requiring complete surgical removal of the scalp. There are no effective medical alternatives to treat this
condition. Whole genome molecular profiling experiments led to the discovery of an attractive molecular target in
these skin tumour cells, named tropomyosin receptor kinase (TRK), upon which these cells demonstrate an
oncogenic dependency in preclinical studies. Recently, the development of an ointment containing a TRK inhibitor
(pegcantratinib — previously CT327 — from Creabilis SA) allowed for the assessment of TRK inhibition in tumours
from patients with inherited CYLD mutations.
Methods/design: Tropomysin Receptor Antagonism in Cylindromatosis (TRAC) is a two-part, exploratory, early phase,
single-centre trial. Cohort 1 is a phase 1b open-labelled trial, and cohort 2 is a phase 2a randomised double-blinded
exploratory placebo-controlled trial.
Cohort 1 will determine the safety and acceptability of applying pegcantratinib for 4 weeks to a single tumour on a
CYLD mutation carrier that is scheduled for a routine lesion excision (n = 8 patients). Cohort 2 will investigate if CYLD
defective tumours respond following 12 weeks of treatment with pegcantratinib. As patients have multiple tumours,
we intend to treat 10 tumours in each patient, 5 with active treatment and 5 with placebo. Patients will be allocated
both active and placebo treatments to be applied randomly to tumours on the left or right side. The target is to treat
150 tumours in a maximum of 20 patients. Tumour volume will be measured at baseline and at 4 and 12 weeks. The
primary outcome measure is the proportion of tumours responding to treatment by 12 weeks, based on change in
tumour volume, with secondary measures based on adverse event profile, treatment compliance and acceptability,
changes in tumour volume and surface area, patient quality of life and pain.
(Continued on next page)
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Discussion: Interventions for rare genetic skin diseases are often difficult to assess in an unbiased way due to small
patient numbers and the challenges of incorporating adequate controls into trial design. Here we present a single-centre,
randomised, placebo-controlled trial design that leverages the multiplicity of tumours seen in an inherited skin tumour
syndrome that may inform the design of other studies in similar genetic diseases.
Trial registration: International Standard Randomised Controlled Trial Number Registry, ISRCTN75715723. Registered on
22 October 2014.
Keywords: CYLD defective tumours, Tropomyosin receptor kinase (TRK) inhibitor, Cylindromatosis, TRK inhibition,
Pegcantratinib, CYLD
Background
Patients who inherit germline mutations in a tumour
suppressor gene called CYLD develop multiple, disfigur-
ing, hair follicle tumours on the head and neck. The
prognosis is poor, with up to one in four mutation car-
riers requiring complete scalp excision typically at the
age of 55 [1]. These patients also have numerous
tumours on the trunk that warrant surgical excision due
to pain, ulceration or necrosis. Tumours have a predilec-
tion to develop on the external ear and in the ear canal,
resulting in conductive deafness. Tumours arising on
genital skin result in sexual dysfunction. These patients
require repeated lifelong surgery to control the tumour
burden. There are no effective medical alternatives to
treat this orphan disease, which is thought to affect
approximately 1 in 100,000 of the UK population [2].
This trial aims to examine the potential of a repurposed
topical treatment to inhibit, and possibly prevent,
tumour growth.
The impact of the disfiguring appearance on the quality
of life of patients with this condition and the recurrent
surgical treatments further emphasise the importance of
this work. Patients find surgical interventions painful and
time-consuming, and may have limited function and abil-
ity to work in the weeks following surgery. This scenario,
and its impact on National Health Service (NHS) re-
sources, could be revolutionised by an ointment that
CYLD mutation carriers could apply to tumours when
they first develop. This may inhibit tumour growth and
subsequently reduce the number of surgical interventions
required. As these tumours often develop on the head and
neck, the reduction in disfiguring tumours and surgery
would have a positive effect on patient quality of life. Fur-
thermore, the reduced referral for specialist interventions
such as surgery and lasers would free up these precious
resources as well as reduce the patient pathway time.
Currently, these tumours are excised by specialists in
dermatology and plastic surgery, with patients requiring
multiple procedures over the course of a lifetime.
Patients with CYLD mutations have complex care needs,
warranting the input of different specialists in their man-
agement. Some procedures, such as laser resurfacing,
represent a costly and scarce resource. Extensive surgical
procedures such as scalp excision and skin grafting may
warrant a general anaesthetic and an inpatient stay.
Tropomyosin receptor kinase (TRK) was discovered as
a candidate target following a search for targetable
kinases in inherited CYLD defective tumours using an
unbiased genetic approach. DNA and RNA expression
changes in fresh, snap-frozen tumours compared to
adjacent, unaffected skin were characterised. This led to
two key discoveries [3]. Firstly, the genetic changes in
these tumours were limited, with restriction to loss of
CYLD being the only detectable change seen. This
homogeneity was exciting, as it implied that a targetable
kinase discovered on this genetic background would be
seen in the majority of tumours. Secondly, we discovered
overexpression of TRK selectively in the tumour cells.
These tumour cells overexpressed TRKB and TRKC in
almost all tumours examined. The mechanism by which
loss of functional CYLD results in perturbation of TRK
homeostasis is not fully understood. TRK signalling has
been shown to confer a survival advantage to tumour
cells by increasing resistance to apoptosis and cell prolif-
eration [4–6]. TRK has been increasingly recognised to
be an oncogenic kinase that is overexpressed in several
malignancies, including leukaemia and breast cancer.
We demonstrated that CYLD defective tumour primary
cell culture models on three-dimensional tissue culture
scaffolds were highly sensitive to nanomolar levels of
TRK inhibition. Proof of principle that inhibition of a
key signalling pathway can restrain skin tumour growth
has been described in another inherited skin tumour
condition, naevoid basal cell carcinoma syndrome. In
this condition, the tumour phenotype conferred by
germline mutations in a tumour suppressor gene PTCH
is inhibited by a small molecule inhibitor targeting
Hedgehog signalling. This has resulted in a reduction in
tumour volume and the number of surgical procedures
that patients with this condition require [7]. TRK inhibi-
tors have so far been only available in oral formulations,
but the advent of pegcantratinib has made validation in
a patient-relevant model possible with minimal risk of
systemic adverse effects.
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There are no effective medical alternatives to treat this
condition, and the TRK inhibitor pegcantratinib may
represent a first-in-class agent for the management of
this condition if shown to be safe and effective in this
trial. Pegcantratinib uses ’low systemic exposure’ tech-
nology via a mini-pegylation approach that generates
molecules with physicochemical and pharmacological
properties that make them suitable for topical use. Safety
data are available from six completed studies where peg-
cantratinib has been applied topically at concentrations
of up to 0.5% w/w for up to 8 weeks in 36 healthy volun-
teers and 188 patients with psoriasis or eczema [8, 9].
These studies have shown that pegcantratinib is well
tolerated with a low incidence of adverse events and ap-
plication site reactions. Pharmacokinetic samples taken
in these studies confirm the absence of pegcantratinib in
the systemic circulation (assay detection level 5 ng/ml),
which is consistent with animal data and supportive of
the theory that absorption of pegcantratinib via the skin
is low following topical application.
This single-centre, early phase trial aims to evaluate an
innovative approach towards managing the multiple
tumours that arise in CYLD mutation carriers. This ap-
proach involves the use of pegcantratinib, which targets
TRK expressed by the tumour cells in these patients. This
selective targeting could lead to the inhibition of tumour
growth and resolution of existing tumours. The prospect
of being able to inhibit TRK focally in the skin using an
ointment vehicle for drug delivery, without the systemic
side effects seen with other TRK inhibitors [10], is an at-
tractive option. Positive results would support a larger,
multicentre, definitive trial which, if proved effective, could
lead to an improvement in quality of patient care and im-
proved cost efficiency, which are key NHS priorities.
Methods/design
Aims and objectives
This is an investigator-initiated trial to determine the
safety and preliminary efficacy of pegcantratinib in
patients with inherited CYLD defective skin tumours.
The primary objective in cohort 1 of the trial is to de-
termine the safety of pegcantratinib application in CYLD
mutation carriers. The primary objective in cohort 2 of
the trial is to investigate if CYLD defective tumours
respond to treatment with pegcantratinib.
The secondary objective for the TRAC trial in cohort
2 is to attempt to delineate the mechanism by which
pegcantratinib and TRK inhibition may exert an effect
on tumour volume.
Trial design
This is a two-part, single-centre, phase 1b/2a trial inves-
tigating the safety and response of pegcantratinib in
CYLD defective tumours.
Cohort 1 design
This is a phase 1b open-label clinical trial to determine
the safety of applying pegcantratinib to a preselected sin-
gle tumour in a CYLD mutation carrier that is scheduled
for routine excision. Cohort 1 will determine the safety of
targeting TRK in this patient population. A preliminary
group of eight patients (who are CYLD mutation carriers)
will receive daily doses (using a standardised spatula) of
the topical TRK inhibitor pegcantratinib (0.5% w/v) for
4 weeks to a preselected single tumour once a day. The
treated site will be clinically assessed for skin inflamma-
tion using a modified version of the Draize score test for
signs of local site reaction. The modified Draize score [11]
is described in more detail in the ‘Outcome measures’ sec-
tion (see also Additional file 1) later in the paper. Lack of
any unexpected trial-related adverse site reactions is indi-
cated by a modified Draize score of 3 or below over
4 weeks of treatment. Lack of reactions in at least five of
eight treated patients will allow the trial to progress to co-
hort 2, following recommendation from an independent
Data Monitoring Committee (DMC). As the gene dosage
of CYLD in these patients is reduced in normal skin com-
pared to healthy controls, this safety trial will determine
safety in a CYLD mutation carrier population before look-
ing at the efficacy of the drug in cohort 2.
Patients with a tumour that has been scheduled for ex-
cision will be eligible for inclusion in this cohort. Each
patient will be required to apply pegcantratinib ointment
to the tumour only for the 4-week interval leading up to
surgery following screening and enrolment into this trial.
An additional Consolidated Standards Of Reporting Tri-
als (CONSORT) diagram for cohort 1 shows this process
(see Additional file 2). The treated site will be assessed
by a clinician for signs of local site reaction. A patient
treatment questionnaire will be used to assess the pa-
tients’ acceptability of the treatment. Patients will also be
asked to complete a general quality-of-life measure, the
European Quality of Life-5 Dimensions (EQ5D) scale,
and a dermatology-specific quality-of-life measure, the
Dermatology Life Quality Index (DLQI), before com-
mencing treatment in order to assess the impact of mul-
tiple CYLD defective tumours on their quality of life and
to assess the patients’ perceptions of the disease. These
data have not been captured in this patient population
previously. If the trial is successful and the treatment is
developed in future multicentre clinical trials, these data
would be requested as a longitudinal measure.
Tumours excised will undergo routine analysis, and
some of the samples will be snap-frozen and stored.
They will be used for further mechanistic studies and
stored for potential future analysis. The end of cohort 1
will be the date when data are obtained on the last
remaining cohort 1 patient completing 4 weeks of
treatment.
Cranston et al. Trials  (2017) 18:111 Page 3 of 12
Cohort 2 design
This is a single-centre, phase 2a, within-patient and
randomized-by-tumour, double-blind, placebo-controlled
trial to investigate if CYLD defective tumours respond to
pegcantratinib. We will need 150 tumours to complete the
trial; recruitment will continue until we have the 12-week
assessment for the 150 tumours. We anticipate that 15–20
patients will need to be recruited to achieve this. Patients
will typically have 8 or 10 eligible tumours each.
Patients will be randomised to receive active treatment
on either the left or right side of the body, with the other
side receiving placebo. Four or five tumours on each side
will be identified at baseline for measurements during
the 12-week treatment period.
Photographs will be taken and the tumours numbered
clearly; this information will be offered to the patients,
who can then refer to the tumour maps. Patients will be
shown how to apply treatments using disposable gloves
to prevent cross-contamination and given a detailed in-
struction sheet for reference. Volume measurements will
be taken at baseline and at weeks 4 and 12 at scheduled
visits. An additional CONSORT diagram and a pictorial
overview for cohort 2 show this in more detail (see
Additional files 3 and 4). All tumours will be assessed
for tumour volume using the Life-Viz stereoscopic
imaging system by a blinded assessor [12]. Patients
will record application of treatment in a patient diary.
Patients will be asked if any of the selected tumours
have any associated pain (type and intensity) at base-
line, and this question will be repeated at 4 and
12 weeks. After 12 weeks, one tumour that is treated
with the active treatment and one tumour that has
been treated with placebo will be biopsied to assess
histological and immunohistochemical changes.
The placebo- and pegcantratinib-treated samples will
undergo gene expression profiling to delineate the
mechanism by which TRK inhibition may exert an effect
on tumour volume. Tumours will be assessed for gene
expression changes following TRK inhibition using RNA
sequencing.
The end of cohort 2 will be when the last cohort 2
patient completing a 12-week assessment brings the
number of assessed tumours to 150. Three months
(12 weeks) has been selected as the trial endpoint,
following discussions with five affected patients. This
period of treatment is in keeping with most topical treat-
ments for skin growths, which are typically given for
1–3 months. It is expected that longer periods may
have a negative effect on trial adherence.
Trial setting and target population
The TRAC trial is a single-centre trial based in Newcastle
upon Tyne, UK.
An overview discussing the tumours seen in these pa-
tients, the natural history and the distribution is relevant
to the design and outcome measurement in this trial.
Key points are as follows:
1. CYLD mutation carriers develop multiple CYLD
defective tumours, typically from the onset of
puberty. These tumours (principally cylindromas,
spiradenomas and trichoepitheliomas) are recognised
to affect the head and neck as well as the torso and
pubic skin.
2. We have studied the distribution of these tumours;
they can be varied in size and location. Whilst
penetrance is similar in males and females, severity
appears to be increased in females [1].
Adult patients will be recruited from genotyped pedi-
grees with known CYLD mutations or from those who
have a clinical phenotype compatible with this diagnosis,
namely multiple cylindromas, spiradenomas or trichoe-
pitheliomas. The patients recruited in cohort 1 will be
those requesting and deemed suitable for surgery for
tumour removal. These tumours will typically be larger
ones that are painful or causing dysfunction. The dis-
tinction from the smaller lesions that are to be recruited
in cohort 2 is reflected in the respective inclusion cri-
teria described below.
Cohort 1 inclusion criteria
The cohort 1 inclusion criteria are as follows:
 Males and females aged 18 years and older.
 Patients from genotyped pedigrees with known
CYLD mutations or who have a clinical phenotype
compatible with this diagnosis.
 Patients who are suitable for the trial will have at
least one eligible tumour.
 The eligible tumour will be scheduled for removal
>4 weeks from consent.
 The eligible tumour must be no more than 3 cm in
size.
 For women of childbearing age, a negative
pregnancy test is required prior to study entry and
on completion of trial treatment. The patient must
be using an adequate contraception method, defined
as established use of oral, injected or implanted
hormonal methods of contraception, placement of
an intrauterine device (IUD) or intrauterine system
(IUS), barrier methods of contraception (condom or
occlusive cap), male sterilisation or true abstinence.
The patient must agree to continue using this
method throughout the trial and for at least 2 weeks
after stopping trial treatment.
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 Sexually active men must agree to use barrier forms
of contraception.
 The recruiting clinician must be confident that the
patient understands the consent process and has the
capacity and willingness to provide fully informed
consent for participation in the trial.
Cohort 1 exclusion criteria
The cohort 1 exclusion criteria are as follows:
 Patients aged <18 years.
 Patients without CYLD defective tumours.
 CYLD defective tumours which are ulcerated (these
tumours will be managed according to standard
practice of care).
 An eligible tumour that is due to be removed <4 weeks
from consent.
 Women who are pregnant or lactating.
 Women of childbearing age and sexually active men
who do not wish to use contraception whilst on the
study.
 Patients exhibiting severe incapacity of higher
function such that fully informed consent cannot be
achieved (to be determined by clinical judgement).
 Use of any other topically administered treatments
at the treatment site.
Cohort 2 inclusion criteria
The cohort 2 inclusion criteria are:
 Males and females aged 18 years and older.
 For women of childbearing age, a negative
pregnancy test is required prior to study entry and
on completion of trial treatment. The patient must
be using an adequate contraception method defined
as established use of oral, injected or implanted
hormonal methods of contraception, placement of
an IUD or IUS, barrier methods of contraception
(condom or occlusive cap), male sterilisation or true
abstinence. The patient must agree to continue
using this method throughout the trial and for at
least 2 weeks after stopping the trial medication.
 Sexually active men must agree to use barrier forms
of contraception.
 Patients from genotyped pedigrees with known CYLD
mutations or those who have a clinical phenotype
compatible with this diagnosis.
 Patients will optimally have 8–10 eligible tumours.
 Eligible tumours will be ideally less than 1 cm in
diameter and no more than 2 cm in diameter at the
base.
 Eligible tumours must be spaced at least 1 cm apart
from other eligible tumours to avoid cross-
contamination.
 The recruiting clinician must be confident that the
patient understands the consent process and has the
capacity and willingness to provide fully informed
consent for participation in the trial.
 Patients who have completed cohort 1 without adverse
reaction and after completing a minimum 2-week
treatment-free washout period.
Cohort 2 exclusion criteria
The cohort 2 exclusion criteria are:
 Patients aged <18 years.
 Patients without multiple CYLD defective tumours.
 Women who are pregnant or lactating.
 Women of childbearing age and sexually active men
who do not wish to use contraception whilst on the
study.
 CYLD defective tumours which are ulcerated or
have recently changed (these tumours will be
managed according to standard practice of care).
 Patients exhibiting severe incapacity of higher
function such that fully informed consent cannot be
achieved (to be determined by clinical judgement).
 Significant concurrent illness.
 Patients who developed an adverse reaction to
pegcantratinib in cohort 1 (modified Draize score of
4 or above).
 Patients who have taken part in cohort 1 and not
completed a minimum 2-week treatment-free washout
period.
 Large tumours of >2 cm base diameter will not be
eligible.
 Any tumour within 10 cm of an excision scar of a
cohort 1-treated site will not be eligible.
 Use of any other topically administered treatments
at the treatment site.
Screening, recruitment and consent
CYLD mutation carrier patients known to the clinical
genetics and dermatology department in Newcastle will
be reviewed by the clinical team to verify that they meet
the trial inclusion criteria. Eligibility screening logs will
be completed by the investigator, or delegate, to docu-
ment participants’ fulfilment of the entry criteria for all
patients considered for cohort 1 and cohort 2 and subse-
quently included or excluded. The eligibility screening
logs will record the potential patient’s initials, screening
date, outcome of screening, reason patient was ineli-
gible/declined and consent date. Screening logs will also
record the number of tumours each patient has for
consideration for cohort 2.
Patients will be either approached during a routine
outpatient appointment or invited in writing to attend a
clinical appointment to discuss the trial. Where patients
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are likely to be travelling long distances, we will enclose
a trial invitation letter and trial information sheet with
their appointment letter. This will allow them more time
to consider whether they are interested in taking part. If
a patient is happy to do so, it is feasible for screening,
recruitment procedures and baseline visit to be com-
pleted over 24 hours. This may be necessary where pa-
tients are travelling long distances so that inconvenience
to patients is minimised. Screening is also permitted to
occur a maximum of 7 days prior to randomisation in
order to ensure that all screening data can be collected.
Female patients who are of childbearing age will be
given urine-based pregnancy tests prior to being rando-
mised into either cohort 1 or cohort 2 of this trial. In co-
hort 2 these tests will be repeated at subsequent visits.
The clinical team members with delegated permission
will explain the trial procedures to the patients and give
them information about the trial treatments in cohort 1
or cohort 2 as appropriate (depending on which part of
the trial is in progress). Prior to consent, patients will
also be given a trial Patient Information Sheet (PIS) to
take with them and read. They will be given opportun-
ities to ask questions and as much time as they need
(minimum 24 hours) to decide whether or not they wish
to take part.
Those wishing to take part will provide written in-
formed consent by signing and dating the trial consent
form, which will be witnessed and dated by a member of
the research team with documented, delegated responsi-
bility to do so. For subjects who cannot consent for
themselves, an appropriate independent witness will
provide written consent. Only after written informed
consent has been obtained will patients undergo any
further trial-specific screening (i.e. screening that cannot
be done by simple review of medical notes, such as preg-
nancy tests) and baseline clinical assessment, including
skin examination. The original signed consent form will
be retained in the Investigator Site File, with a copy in
the clinical notes and a copy provided to the participant.
The participants will specifically consent to their general
practitioner being informed of their participation in the
trial, and a standard letter will be sent out. The eligibility
screening log will be updated to record the patient en-
tering the trial. The right to refuse to participate without
giving reason will be respected.
Due to the small subject population, the PIS and con-
sent form for the trial will be available only in English.
Via local NHS arrangements, interpreters will be made
available for all visits of patients who require them either
for verbal translation or for deaf subjects wishing to take
part in the trial. Consent will not be taken from any par-
ticipant unless the research team are confident he/she
understands the information and can give fully informed
consent. The screening assessment (as per clinical
practice) must be fully completed and eligibility con-
firmed by an investigator prior to enrolment (cohort 1)
or randomisation (cohort 2).
Intervention
The TRK inhibitor pegcantratinib is a topical investiga-
tional medicinal product (IMP) currently being devel-
oped by Creabilis Limited for the treatment of pruritus
and pain in dermatological conditions. This trial is the
first trial to investigate the use of pegcantratinib in pa-
tients with CYLD defective skin tumours; however, the
drug has been given to 36 healthy volunteers and 188
patients in previous clinical trials [8, 9]. At the first trial
visit, patients will have their tumours for drug adminis-
tration identified. Details for each cohort are stated in
the inclusion/exclusion criteria. Patients will then be
instructed on how to administer the trial medication and
given instructions to take with them for reference. A
new disposable glove should be used for each separate
administration and disposed of after use. The amount of
drug will be measured using a provided spatula. The pa-
tient will also be instructed to wash the area with warm
water before administration. The patient will cover the
full tumour evenly, being careful to not apply treatment
to any surrounding areas. The ointment will be applied
in the evening, 2 hours before bedtime.
In cohort 1 active trial medication containing pegcantra-
tinib at 0.5% w/w will be provided as ointment in 20-g
glass jars. Patients will be provided with a spatula to help
them to apply the correct amount of ointment. The dose
will be one application (two standardised spatulas) in the
evening to each tumour as directed at the first visit by the
research nurse/doctor. Application will be recorded in a
patient diary. In cohort 1 the participants will treat their
selected tumour with the active treatment for a 4-week
period. Additional file 5 shows the full schedule of events
(Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) figure) for cohort 1.
In cohort 2 active and placebo trial medication will be
provided at baseline and at the week 4 visit to supply
enough ointment for the 12-week period. Application
will be as outlined for cohort 1 but one dose will be one
standardised spatula per tumour. Patients will record ap-
plication of treatment in a patient diary. In cohort 2 all
participants will be treating tumours on one half of the
body with active pegcantratinib and on the other half of
the body with placebo according to the randomisation
allocation for a 12-week period. A 3-day visit window is
allowed for the second dispensing visit at week 4. The
full schedule of events (SPIRIT figure) for cohort 2 is
shown in Additional file 6.
A telephone contact number will also be provided so
participants can contact a member of the research team
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if required. Any participant reporting significant side
effects will be reviewed in clinic.
Concomitant medication
No formal interaction studies have been performed; the
clinical protocol excludes patients who are using any
other topically administered treatment at the treatment
site. As systemic levels are not detectable when applied
topically, interaction with other systemic agents is not
expected to be an issue. A complete listing of all con-
comitant medication received during the treatment
phase must be recorded in the relevant Case Report
Form (CRF).
Randomisation
A member of the trial team (as outlined in the delega-
tion log) will recheck and confirm eligibility of patients
for cohort 2 prior to randomisation. Randomisation will
be at the per-patient level, randomising active and
placebo treatments to left- or right-sided application.
There will be no stratification at randomisation in this
early phase trial. The statistics team will be responsible
for preparing the allocation lists. Randomisation will be
administered centrally by the Newcastle Clinical Trials
Unit Internet-accessed secure web-based system, which
provides ease of operation with in-built validation/
plausibility checks at time of data entry. The Principal
Investigator (PI) at site or an individual with delegate au-
thority will access the web-based randomisation system.
Patient screening ID and initials will be entered into the
web-based system. Patients will be allocated both active
and placebo treatments to be applied randomly to left or
right tumours (e.g. L = active; R = placebo or L = placebo;
R = active, where the terms L and R refer to the patient’s
left and right side). Patients allocated to a specific group
(e.g. L = active; R = placebo) will remain in this same
group when prescriptions are dispensed at baseline and at
week 4. Specific training will be given at site initiation.
Four or five tumours matched for size will be selected
on each side of the patient. Each tumour will be assigned
a number to facilitate assessments, and then each side of
the patient will be allocated randomly to receive either
active ointment or placebo ointment. Photographs will
be taken and the tumours numbered clearly so that the
patient can refer to the tumour maps to ensure the cor-
rect tumour is being treated from the correct ointment
jar. Tumours will be marked with a 2-mm dot using a
permanent marker designed for use on the skin, which
the patient will renew as necessary. Tumours within the
hair will have a small amount of surrounding hair
trimmed to allow the patient to locate the tumour by
feel, and for volume assessments.
Blinding
Cohort 2 patients and investigators will be blinded to
the treatment allocation. Those responsible for tumour
volume measurements, histology assessments and mo-
lecular analysis will also be blinded to treatment alloca-
tion. The Trial Management Group including the Trial
Manager will be blind to the treatment allocation. The
trial statistician will provide data to the independent
Data Monitoring Committee (DMC) by trial arms A and
B (arms will be either 'right active left placebo' or 'left
active right placebo'), with an option for unblinding in
the closed session (excluding members of the Trial
Management Group).
Following the unlikely event of a code break, patients
will continue to be followed up if they agree to do so. If
the unblinding reveals that the cause was the placebo
ointment, patients will be offered the continuation of
the trial medication as per the randomisation if they
wish. The analysis of the trial will reflect any unblinding
as specified in the statistical analysis plan (SAP).
Code breaks will not be routinely performed for all
participants who complete trial treatment, but all pa-
tients may be informed of their allocations once the trial
analysis is complete and the data released to the PI. At
the final visit, the blinding will be assessed by asking the
participants: Which side was receiving active treatment?
Why do you think this? on the patient treatment ques-
tionnaire. To avoid bias, the treatment assessor will be
asked to record his/her own opinion on a separate CRF
and prior to asking the participants their opinions.
Outcome measures
The primary outcome measure for cohort 1 is the num-
ber of severe treated skin site reactions defined as a
modified Draize score of 4 or above after 4 weeks of
treatment. Additional file 1 describes the modified
Draize score, a measure of skin inflammation, in more
detail. Secondary outcome measures for cohort 1 are:
 Patient reported quality-of-life tools (EQ5D and
DLQI) measured at baseline
 Patient acceptability to trial treatment according to
the patient treatment questionnaire measured at the
end of treatment visit (week 4)
 Adverse events, graded as mild, moderate or severe,
within a planned 4-week treatment period
 Compliance as reported in the patient diary, including
reasons for non-compliance, recorded throughout the
4-week treatment period.
The primary outcome measure for cohort 2 is the pro-
portion of tumours responding to treatment by 12 weeks
in both actively treated lesions and placebo-treated
lesions. Secondary outcome measures for cohort 2 are:
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 Change in tumour volume from baseline
(pre-randomisation) to 12 weeks assessed by a
tumour volume measuring device
 Adverse events, graded as mild, moderate or severe,
within a planned 12-week treatment period
 Compliance as reported in the patient diary, including
reasons for non-compliance, recorded throughout the
12-week treatment period
 Confirmation of the definition of response (currently
according to WHO RECIST)
 Expression of targets of TRK signalling in tumour
biopsies as determined by QPCR and
immunohistochemistry
 Patient reported quality of life tools (EQ5D and
DLQI) measured at baseline
 Assessment of acceptability of trial treatment
according to the patient treatment questionnaire
measured at the end of treatment visit (week 12)
 Patient reported pain using a trial-specific Patient
Pain Assessment Form at 0, 4 and 12 weeks.
In cohort 1 baseline photographs of the selected
tumour scheduled for excision will be taken for refer-
ence for the eight patients.
In cohort 2 photographs with clearly numbered tu-
mours will be offered to the patients so they can refer to
the tumour maps to ensure the correct tumour is being
treated from the correct ointment jar and kept at site for
reference.
Tumour volume assessment
All tumours will be assessed for tumour volume using
the Life-Viz stereoscopic imaging system by a blinded
assessor [12]. This is a validated system that has been
shown to be a highly sensitive and reproducible method
to assess skin tumour volume assessments. The device
will be used to measure the volume of individual tu-
mours. The region of interest, once defined, will be mea-
sured as a base area and a raised volume compared to
surrounding skin. This measurement of volume and sur-
face area will be taken at 0, 4 and 12 weeks in the trial
for each tumour. Tumour-level change in volume at
4 weeks will be reported as mean percentage change
(with 95% confidence interval) by randomised treatment
group. In order to assess the possibility of differing per-
centage changes being influenced by initial tumour size,
the mean percentage change from baseline to 4 weeks
and baseline to 12 weeks will be reported by baseline
tumour diameter categories. Mean volume and mean
percentage change will be displayed graphically by treat-
ment group and by baseline tumour diameter category.
A repeated measures analysis will look at the mean
volume over time at baseline, 4 weeks and 12 weeks,
accounting for multiple tumours within individual
patients and including randomised treatment group as a
covariate.
Tumour biopsies
For cohort 1 patients, at the end of treatment visit (week
4), the routinely excised tumour will undergo routine
analysis and some of the sample will be snap-frozen and
stored. This sample will be stored with a view to devel-
oping a pegcantratinib skin quantitation assay. Partici-
pants will have the option to consent to samples
potentially being used in future studies relating to the
title of this trial.
For cohort 2 patients, at the end of treatment visit
(week 12), one tumour that has been treated with active
treatment and one tumour that has been treated with
placebo will be biopsied to assess histological and immu-
nohistochemical changes and transcriptomic profiling.
Immunohistochemical analyses and transcriptomic
profiling
Tumour samples will be assessed by a pathologist who is
blinded to the treatment applied to the specimens. Im-
munostaining using antibodies against phosphorylated
forms of the mitogen-activated protein (MAP) kinase
pathway and BCL2 (an antiapoptotic protein) will be
assessed to determine if TRK inhibition is leading to an-
ticipated cell death via suppression of the expected
downstream targets of TRK. Tissue concentrations of
pegcantratinib will also be assessed in a representative
portion of samples.
Gene expression profiling of tumour samples to com-
pare 12 placebo- and 12 pegcantratinib-treated samples
will be performed as indicated above.
Data handling and record keeping
The quality and retention of data that are collected as
part of this trial are the responsibility of the Principal In-
vestigator, Dr. Neil Rajan. All trial data will be retained
in accordance with the latest directive on Good Clinical
Practice (GCP) (2005/28/EC) and local policy. Data will
be handled, computerised and stored in accordance with
the Data Protection Act 1998. Patients will be identified
by a unique trial number. Data will be recorded by
authorised site staff on electronic Case Report Forms
(eCRFs) and stored on a secure validated MACRO data-
base system managed by Newcastle Clinical Trials Unit
(NCTU). Caldicott approval will be sought at The New-
castle upon Tyne NHS Foundation Trust site to enable
the collection of personal identifiable information for
purposes of trial administration (including arranging pa-
tient assessments) and maintaining accurate screening
records. Data will be extracted from MACRO for statis-
tical analyses in STATA (version 14). STATA data files
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are stored securely and backed up on a Newcastle
University server.
Trial compliance and withdrawal
Where feasible, trial visits will coincide with routine
clinical follow-up to enhance the likelihood of good
compliance. Visit windows of +/– 3 days should ensure
visit attendance; non-attendance for trial visits will
prompt follow-up by telephone. Compliance with trial
medication will be assessed by checking the patient diar-
ies. Trial drug accountability will be assessed and docu-
mented by local pharmacy. The clinical team will also
perform review of any returned trial medication at each
trial visit to identify any obvious compliance concerns
and address them immediately with the participant.
The trial drug must be discontinued if:
 The participant decides they no longer wish to
continue.
 Cessation of the trial drug is recommended by the
investigator.
 A participant becomes pregnant.
 Any significant medical condition occurs (in the
judgement of the site investigator).
 Localised reactions occur: Any patient reporting
treatment site reactions will be assessed in the clinic.
A modified Draize score of 4 or above would result
in discontinuation of the drug. In the event of such
an adverse reaction, blinding may need to be broken
to determine if the reaction is related to the
application of the trial drug to the treated site.
Once the blind is broken, the trial drug will need to
be discontinued if it is found to be responsible for
the adverse event.
 Systemic reactions occur: Any other reported side
effects/adverse events that the patient experiences
during the trial will be assessed by the Principal
Investigator. If clinically appropriate, the patient will
be reviewed in clinic and a decision made regarding
discontinuation of the trial drug if it is feasible that
this is related to the trial drug.
Participants have the right to completely withdraw
from the trial at any time for any reason and without
giving a reason. The investigator also has the right to
withdraw patients from the trial drug in the event of
inter-current illness, adverse events, serious adverse
events, suspected unexpected serious adverse reactions,
protocol violations, cure, administrative reasons or
other reasons. It is understood by all concerned that an
excessive rate of withdrawals can render the trial unin-
terpretable; therefore, unnecessary withdrawal of pa-
tients should be avoided. Should a patient decide to
withdraw from the trial, all efforts will be made to
report the reason for withdrawal as thoroughly as pos-
sible. Should a patient withdraw from the trial drug
only, efforts will be made to continue to obtain follow-
up data, with the permission of the patient.
In both cohorts, additional participants may be
recruited, provided withdrawal is not related to safety
issues, to preserve the recruitment target based on
patients/tumours completing treatment.
Statistical considerations
Statistical definitions and analyses
All statistical analyses will follow a trial-specific prede-
termined SAP, written and signed off prior to any statis-
tical analysis of the trial data (excepting recruitment)
and stored in the Trial Master File.
All cohort 1 patients will contribute to the analysis
based on the total number recruited. The primary out-
come measure is the number of patients with severe or
very severe treated skin site reactions as determined by
modified Draize score (see Additional file 1). Patient per-
ception of treatment is a secondary outcome measure as
measured by the patient treatment questionnaire. Posi-
tive patient perception will be reported descriptively as a
proportion of the number of patients recruited. Statistical
analysis for all outcome measures will be exploratory
based on descriptive data. Continuous measurements (in-
cluding quality-of-life measures) will be summarised and
reported as medians and ranges (inter-quartile ranges).
Categorical data (including proportions of patients with
positive patient perception and with adverse events) will
be summarised and reported as percentages and confi-
dence intervals (95%). Quality-of-life tools (EQ5D, DLQI)
will be scored according to scoring manuals, and actual
scores will be reported descriptively.
In cohort 2, all tumours will contribute to the analysis
based on the total number randomised (intention-to-
treat population). A secondary analysis will be reported
based on the number of tumours which have been
treated for 12 weeks (per protocol population). The pri-
mary outcome measure is the number of tumours
responding to treatment by 12 weeks reported as a pro-
portion of the number of tumours randomised in the
actively and placebo-treated groups separately.
According to WHO RECIST criteria, a reduction in
30% volume would be sufficient to classify a ‘response’
to treatment in oncology. In this trial we will use this
criterion as an initial benchmark when determining a re-
sponse in this patient population. As such, one of the
outcomes will be to consider alternative definitions of
‘response’ to treatment in this group of patients.
Tumour volume will be measured on 8–10 predeter-
mined identified tumours in each patient prior to ran-
domisation (baseline) and measured again on the same
tumours at 4 and 12 weeks. The change in volume for
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each tumour will be recorded and classified as either
showing a response to treatment or not.
As an early phase trial, statistical analysis will be ex-
ploratory (not based on hypothesis testing) and will be
based on descriptive data presented by treatment group.
Continuous measurements (including change in tumour
volume from baseline) will be summarised and reported
as medians and ranges (inter-quartile ranges). Categorical
data (including proportions of tumours with adverse
events and outcomes from the Pain Assessment Forms)
will be summarised and reported as percentages and
confidence intervals (95%). Since multiple tumours are
sited in individual patients, a secondary analysis based on
a multilevel modelling approach will be undertaken to
investigate the relationship between any change in volume
and randomised treatment accounting for the multilevel
nature of the tumour measurements within patients.
Quality-of-life tools (EQ5D, DLQ) will be scored accord-
ing to manuals and will be reported descriptively.
Sample size
It is anticipated that there will be low numbers of
treatment-related adverse events in cohort 1, and it is
therefore both feasible and pragmatic to recruit eight pa-
tients. Lack of any unexpected trial-related adverse site
reactions is indicated by a modified Draize score of 3 or
below, over 4 weeks of treatment. Lack of reactions in at
least five of eight treated patients will allow the trial to
progress to cohort 2, following recommendation from
an independent Data Monitoring Committee.
For cohort 2, it is feasible and pragmatic that 75
tumours could be measured in each treatment arm (150
tumours in total) in a single centre. This is the first
exploratory trial; as such, the design parameters are pro-
vided as an exemplar of the size of errors that may be
anticipated with these patient numbers. Tumours receiv-
ing placebo treatment are not expected to respond to
treatment, set to be very small at 5% (p0). Using the
Fleming-A’Hern early phase methodology [13], any
response on the experimental treatment <5% (p0) would
not indicate a treatment worthy of further investigation.
A level of efficacy of >15% (p1) would indicate a treat-
ment that warranted further investigation. This level of
efficacy seems clinically plausible and relevant given that
there is no current treatment in use for these patients.
Seventy-five tumours recruited in the experimental arm
would provide associated error levels of 3.4% type I error
(alpha) and 10.8% type II error (beta), acceptable in the
early phase setting. The justification to investigate peg-
cantratinib further is based on observing a minimum
number of responses, referred to as the critical number
in the experimental arm (as specified in the Fleming-
A’Hern design and documented in the Statistical Ana-
lysis Plan). The trial will recruit an equal number of
placebo-treated tumours to provide an unbiased
benchmark.
Trial monitoring
Monitoring of trial conduct and data collected will be
performed by a combination of central review and site
monitoring visits to ensure the trial is conducted in ac-
cordance with GCP. Trial site monitoring will be under-
taken by NCTU. The main areas of focus will include
consent, serious adverse events, essential documents in
trial files and drug accountability and management.
Site monitoring will include the following tasks:
○ All original consent forms will be reviewed as part
of the site file. The presence of a copy in the patient
hospital notes will be confirmed for 100% of
participants.
○ All original consent forms will be compared against
the trial participant identification lists.
○ All reported serious adverse events will be verified
against treatment notes/medical records (source data
verification).
○ The presence of essential documents in the
Investigator Site File and other site files will be
checked.
○ Source data will be verified for primary endpoint data
and eligibility data for 100% of participants entered in
trial cohort 1 and 50% of participants in trial cohort 2.
○ Drug accountability and management will be
checked.
Central monitoring will include the following tasks:
○ All applications for trial authorisations and
submissions of progress/safety reports will be reviewed
for accuracy and completeness prior to submission.
○ All documentation essential for trial initiation will
be reviewed prior to site authorisation.
All monitoring findings will be reported and followed
up with the appropriate persons in a timely manner. The
trial may be subject to inspection and audit by Newcastle
Upon Tyne Hospitals NHS Foundation Trust (NUTH)
under their remit as sponsor and other regulatory bodies
to ensure adherence to GCP. The investigator(s)/institu-
tions will permit trial-related monitoring, audits, REC
review and regulatory inspection(s), providing direct
access to source data/documents.
Trial monitoring will be undertaken by three commit-
tees with separate roles: (1) Trial Management Group
(TMG), (2) Trial Steering Committee (TSC) and (3)
Data Monitoring Committee (DMC). The trial will be
managed through NCTU. The Principal Investigator, Dr
Neil Rajan, will be responsible for the day-to-day trial
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conduct at site. NCTU will provide day-to-day support
for the site and provide training through investigator
meetings, site initiation visits and routine monitoring
visits. Quality control will be maintained through adher-
ence to NCTU SOPs, the trial protocol, SAP, the princi-
ples of GCP, research governance and clinical trial
regulations.
A TSC will provide overall supervision of the trial. The
TSC will consist of independent chair, further independ-
ent clinician, independent consumer representative,
funder representative and Trial Management Group.
The committee will meet before the start of the trial to
make recommendations on the protocol and at least
annually thereafter for the duration of the trial. The
chair of the TSC and the PI can request meetings more
frequently if needed and if also requested by the DMC.
An independent DMC (two independent clinicians
and one independent statistician) will undertake inde-
pendent review and report recommendations to the
TSC. The purpose of this committee will be to monitor
safety in cohort 1 and recruitment, safety and outcomes
in cohort 2. The DMC may request access to unblinded
trial data. The DMC will meet at least three times: at the
start, following completion of cohort 1 data collection
and following completion of cohort 2 data completion.
Trial reporting
The data will be the property of the Principal Investiga-
tor and Co-Investigator(s). Publication will be the
responsibility of the Principal Investigator. We plan to
publish this trial in peer-reviewed journals and to
present data at national and international meetings.
Results of the trial will also be reported to the Sponsor
and Funder, and will be available on their web site. All
manuscripts, abstracts or other modes of presentation
will be led by the Trial Management Group and circu-
lated to the Trial Steering Committee and Funder prior
to submission. Individuals will not be identified from
any trial report. Participants will be informed about their
treatment and their contribution to the trial at the end
of the trial, including a lay summary of the results.
SPIRIT
This protocol has been written in accordance with the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines. Please refer to the
SPIRIT checklist that was submitted alongside this publi-
cation for further details (see Additional file 7).
Discussion
Patients with rare, germline mutations in CYLD develop
multiple primary tumours in the skin. We report a trial
design which allows within-patient placebo controls,
allowing for an unbiased preliminary assessment of TRK
inhibition in skin tumours from these patients. This
design allows the number of tumours required in each
arm to achieve statistical robustness despite the small
number of participants typically seen in rare disease. We
suggest that this model could be attractive to other
researchers involved in rare genetic skin disease.
Trial status
Cohort 1 of the TRAC trial opened to recruitment on 8
March 2015 and completed recruitment on 23 March
2015. Cohort 2 recruited its first patient on 15 September
2015. Recruitment is due to be complete by July 2016.
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Additional file 1: Table showing modified Draize score used to assess
for signs of local site reaction in cohort 1. (PDF 84 kb)
Additional file 2: CONSORT diagram for cohort 1: phase 1b of the trial.
(PDF 82 kb)
Additional file 3: CONSORT diagram for cohort 2: phase 2a of the trial.
(PDF 166 kb)
Additional file 4: Pictorial overview of phase 2a design. (PDF 152 kb)
Additional file 5: SPIRIT figure showing schedule of events in cohort 1
of the trial. (PDF 140 kb)
Additional file 6: SPIRIT figure showing schedule of events in cohort 2
of the trial. (PDF 180 kb)
Additional file 7: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 254 kb)
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